share_log

Sonnet BioTherapeutics Publishes Key Data On SON-1010 IL-12 Fusion Protein In Frontiers In Immunology, Highlighting Mechanism Of Action And Enhanced Tumor Targeting With Patents Secured Through 2039

Sonnet BioTherapeutics Publishes Key Data On SON-1010 IL-12 Fusion Protein In Frontiers In Immunology, Highlighting Mechanism Of Action And Enhanced Tumor Targeting With Patents Secured Through 2039

Sonnet BioTherapeutics在《免疫學前沿》雜誌上發表了關於SON-1010 IL-12融合蛋白的重要數據,突出了作用機制,並通過2039年獲得專利保護,強調增強的腫瘤靶向性。
Benzinga ·  12/04 22:21

Sonnet BioTherapeutics Publishes Key Data On SON-1010 IL-12 Fusion Protein In Frontiers In Immunology, Highlighting Mechanism Of Action And Enhanced Tumor Targeting With Patents Secured Through 2039

Sonnet BioTherapeutics 在《免疫學前沿》雜誌上發表了有關 SON-1010 IL-12 融合蛋白的關鍵數據,突顯其作用機制,並通過到 2039 年的專利確保了增強的腫瘤靶向性。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論